Articles From: Advantest Logs Three Orders for F7000 Series EB Lithography System to Advaxis to Participate in Canaccord Genuity Orphan Drug One-on-One Day


2013/10/22
Advantest Corporation (TSE: 6857, NYSE: ATE) today announced that it has logged its first three orders for its new EB (electron beam) lithography system, the F7000, from the University of Tokyo, the University of Kyoto, and a semiconductor industry customer.
Sign-up for Advantest Logs Three Orders for F7000 Series EB Lithography System investment picks
2014/3/18
http://media.marketwire.com/attachments/201103/23230_Advant.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1098897&ProfileId=051205&sourceType=1 TOKYO, JAPAN --
Sign-up for Advantest New Pin Scale Serial Link Card Continues to Win Market Share With Latest Order From Chinese IC Maker HiSilicon investment picks
2014/3/4
http://media.marketwire.com/attachments/201103/23230_Advant.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1093853&ProfileId=051205&sourceType=1 TOKYO, JAPAN --
Sign-up for Advantest VOICE 2014 Conference to Feature Robust Technical Program With More Than 100 Papers investment picks
http://media.marketwire.com/attachments/201103/23230_Advant.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1037796&ProfileId=051205&sourceType=1 TOKYO --
Sign-up for Advantest's V93000 Smart Scale Selected as Primary Test System by HiSilicon Technologies in Shenzhen, China investment picks
http://media.marketwire.com/attachments/201312/TN-207096_93000A-Class.jpg Advantest's V93000 Smart Scale platform selected by Avago for use in testing optical transceiver devices for high-speed backplane and telecommunication applications.
Sign-up for Advantest's V93000 Smart Scale System Selected by Avago's Fiber Optic Products Division investment picks
2014/1/8
Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857, NYSE: ATE) today announced that its terahertz spectroscopic imaging system TAS7500, which utilizes Advantest’s THz wave technology, has been adopted by Seoul National University.
Sign-up for Advantest’s Terahertz Spectroscopic/Imaging System TAS7500 Adopted by Seoul National University investment picks
2014/3/17
PRINCETON, N.J., March 17, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) , a biotechnology company developing the next generation of cancer immunotherapies, announced that it has signed an agreement with the University of California, San Francisco (UCSF), under which Lawrence Fong, M.D., Professor in the Department of Medicine and principal investigator of the studies at UCSF, will evaluate several new immunotherapy constructs, in addition to ADXS-PSA, each built on the Advaxis proprietary technology.
Sign-up for Advaxis and UC San Francisco to Evaluate Cancer Immunotherapy Constructs in Prostate Cancer investment picks
2014/3/31
PRINCETON, N.J., March 31, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company"), today announced the closing of a previously announced underwritten public offering of 4,692,000 shares of its common stock, including the fully exercised over-allotment option by the underwriters covering 612,000 shares, offered at a price to the public of $3.00 per share.
Sign-up for Advaxis Announces Closing of Public Offering of Common Stock investment picks
2013/10/22
Advaxis, Inc., (NASDAQ: ADXS, ADXSW) , a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced it has closed its public offering of 6,612,500 shares of common stock, and warrants to purchase up to an aggregate of 3,306,250 shares of its common stock, including 862,500 shares and warrants to purchase 431,250 shares that were offered and sold by Advaxis, Inc. pursuant to the full exercise of the underwriters’ over-allotment option, at a price to the public of $4.00 per share and $0.001 per warrant.
Sign-up for Advaxis Announces Closing of Public Offering of Common Stock and Warrants investment picks
2014/1/21
Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 “window of opportunity” study being conducted by the Icahn School of Medicine at Mount Sinai.
Sign-up for Advaxis Announces First Patient Dosed in Phase 1/2 Head and Neck Cancer Study investment picks
2013/10/23
Advaxis, Inc., (NASDAQ:ADXS)(NASDAQ:ADXSW), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in REALISTIC , a Phase 1 study being funded by Cancer Research UK (CRUK) to investigate the use of ADXS-HPV for the treatment of HPV-positive head and neck cancer.
Sign-up for Advaxis Announces First Patient Dosed with ADXS-HPV in Head and Neck Cancer Study investment picks
2014/3/28
PRINCETON, N.J., March 28, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company"), today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 612,000 shares of its common stock at a public offering price of $3.00 per share in connection with its previously announced underwritten public offering of 4,080,000 shares of common stock, bring the total gross proceeds from the offering to approximately $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
Sign-up for Advaxis Announces Full Exercise of Underwriters' Over-Allotment Option investment picks
2013/11/20
Advaxis, Inc ., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that the Icahn School of Medicine at Mount Sinai (ISMMS) will initiate a Phase 1/2 study of ADXS-HPV in 25 patients with Human Papilloma Virus (HPV)-positive head and neck cancer, a type of cancer which is increasing at an epidemic rate.
Sign-up for Advaxis Announces Initiation of Phase 1/2 Trial of ADXS-HPV in Head and Neck Cancer Conducted by Icahn School of Medicine at Mount Sinai investment picks
2014/3/26
PRINCETON, N.J., March 26, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company"), today announced the pricing of an underwritten public offering of 4,080,000 shares of common stock at a public offering price of $3.00 per share.
Sign-up for Advaxis Announces Pricing of Public Offering of Common Stock investment picks
2014/3/26
PRINCETON, N.J., March 26, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company"), today announced that it intends to offer for sale shares of its common stock in an underwritten public offering.
Sign-up for Advaxis Announces Proposed Public Offering of Common Stock investment picks
2013/8/20
Advaxis, Inc. (OTCQB:ADXS) (“Advaxis” or the “Company”) , a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the appointment of Daniel J.
Sign-up for Advaxis Appoints Daniel J. O’Connor President and CEO and Elects Dr. James Patton Non-Executive Chairman of the Board investment picks
Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has appointed Gregory T.
Sign-up for Advaxis Appoints Gregory T. Mayes as Chief Operating Officer investment picks
2014/3/24
PRINCETON, N.J., March 24, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) , a biotechnology company developing the next generation of cancer immunotherapies, announced that it has appointed Sara Bonstein to the position of Chief Financial Officer, Senior Vice President.
Sign-up for Advaxis Appoints Sara Bonstein as Chief Financial Officer, Senior Vice President investment picks
Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that it is one of 54 companies approved to share the $60 million allocation through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program in Fiscal Year 2014.
Sign-up for Advaxis Approved to Receive Cash Allocation Through New Jersey Technology Business Tax Certificate Transfer (NOL) Program investment picks
Advaxis, Inc ., (NASDAQ: ADXS), a leader in developing the next generation of cancer immunotherapies, announced that ADXS-cHER2, its proprietary immunotherapy for the treatment of breast cancer and canine osteosarcoma, was featured on ABC News in an article titled “ Bone Cancer Vaccine for Dogs Shows Promise for Breast Cancer ”. Advaxis sponsored a Phase 1 canine osteosarcoma study, conducted by Dr.
Sign-up for Advaxis Cancer Immunotherapy Featured on ABC News investment picks
2014/3/3
PRINCETON, N.J., March 3, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) , a biotechnology company developing the next generation of cancer immunotherapies, announced that ADXS-cHER2, its proprietary immunotherapy designed to treat women with breast cancer, was featured on CNN in a segment focused on its success in treating dogs with osteosarcoma (bone cancer). The segment includes an interview with Dr.
Sign-up for Advaxis Cancer Immunotherapy Featured on CNN investment picks
2014/3/20
PRINCETON, N.J., March 20, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) , a biotechnology company developing the next generation of cancer immunotherapies, hosted a joint conference call with Aratana Therapeutics (Nasdaq:PETX) today at 8:00 am ET to discuss the recently announced global licensing agreement for Advaxis's ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer.
Sign-up for Advaxis Discusses Global Licensing Agreement for Pet Therapeutics on Conference Call investment picks
2014/2/11
PRINCETON, N.J., Feb.
Sign-up for Advaxis Engages SynCo Bio Partners for Manufacturing of ADXS-HPV, Its Lead Cancer Immunotherapy Program investment picks
2014/1/15
Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced the launch of a suite of online digital corporate communication channels to maintain on-going direct communication with shareholders.
Sign-up for Advaxis Launches Online Communication Channels investment picks
2014/4/1
PRINCETON, N.J., April 1, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) , a biotechnology company developing the next generation of cancer immunotherapies, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for three U.S. patent applications (12/213,696, 13/254,607, and 11/415,271) with claims of each application related to the Company's proprietary cancer immunotherapy platform technology.
Sign-up for Advaxis Receives Notice of Allowance From U.S. Patent and Trademark Office for Three Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy Platform Technology investment picks
2014/3/18
PRINCETON, N.J., March 18, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) , a biotechnology company developing the next generation of cancer immunotherapies, today announced that it has been issued a significant patent from the Japan Patent Office, entitled, "Compositions and Methods for Enhancing Immunogenicity of Antigens". The claims of the patent (patent number 5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical cancer with a term that extends to 2028.
Sign-up for Advaxis Receives Patent in Japan for ADXS-HPV for the Treatment of Cervical Cancer investment picks
Advaxis, Inc ., (NASDAQ:ADXS) , a leader in developing the next generation of cancer immunotherapies, announced today final 18-month survival data from Lm -LLO-E7-15, a randomized Phase 2 study evaluating the safety and efficacy of ADXS-HPV (1x10 9 cfu) (ADXS11-001) with and without cisplatin (40 mg/m2, weekly x5) in 110 patients with recurrent cervical cancer in two treatment arms of 55 patients each.
Sign-up for Advaxis Reports Final 18-Month Survival Data for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 Society for Immunotherapy of Cancer Annual Meeting investment picks
2013/12/9
Advaxis, Inc ., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that it has entered into an exclusive licensing agreement for the development and commercialization of ADXS-HPV with Global BioPharma, Inc. (GBP), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC). TBC is one of the top five pharmaceutical companies in Taiwan and formed GBP solely to focus on the development and commercialization of ADXS-HPV for the treatment of human papillomavirus (HPV)-associated diseases.
Sign-up for Advaxis Signs Exclusive Licensing Agreement for Development and Commercialization of ADXS-HPV in Asia investment picks
2014/2/18
PRINCETON, N.J., Feb.
Sign-up for Advaxis to Participate in Canaccord Genuity Orphan Drug One-on-One Day investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Advantest Logs Three Orders for F7000 Series EB Lithography System to Advaxis to Participate in Canaccord Genuity Orphan Drug One-on-One Day
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity